Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 39, 2013, Pages 15782-15787

  Kirkby, Nicholas S ^a,b   Lundberg, Martina H ^a   Chan, Melissa V ^a   Vojnovic, Ivana ^a   Solomon, Antonia B ^b   Emerson, Michael ^b   Mitchell, Jane A ^b   Warner, Timothy D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anti platelet therapy; Atherothrombosis; Prostacyclin

Indexed keywords

ANTICOAGULANT AGENT; COLLAGEN; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; THROMBIN; TICAGRELOR; ACTIN BINDING PROTEIN; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CALCIUM; CELL ADHESION MOLECULE; CYCLIC AMP; CYCLIC GMP; FIBRINOGEN RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHODIESTERASE INHIBITOR; PHOSPHOPROTEIN; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; RAP1 PROTEIN; VASODILATOR STIMULATED PHOSPHOPROTEIN; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; COMPETITIVE INHIBITION; DRUG HALF LIFE; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; WESTERN BLOTTING; ANTI-PLATELET THERAPY; BIOLOGICAL MODEL; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PHOSPHORYLATION; SECRETION (PROCESS); THROMBOCYTE; THROMBOSIS; DRUG EFFECTS;

ANTI-PLATELET THERAPY; ATHEROTHROMBOSIS; PROSTACYCLIN;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; BLOOD PLATELETS; C-REACTIVE PROTEIN; CALCIUM; CELL ADHESION MOLECULES; CYCLIC AMP; CYCLIC GMP; ENZYME ACTIVATION; EPOPROSTENOL; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; MICROFILAMENT PROTEINS; MODELS, BIOLOGICAL; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHODIESTERASE INHIBITORS; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RAP1 GTP-BINDING PROTEINS; RECEPTORS, PURINERGIC P2Y12; THROMBIN;

EID: 84884617086     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218880110     Document Type: Article

References (32)

1. Meadows TA, Bhatt DL (2007) Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 100(9):1261-1275.
2. Cattaneo M (2007) Platelet P2 receptors: Old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 5(1):45-55.
3. Warner TD, Nylander S, Whatling C (2011) Anti-platelet therapy: Cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol 72(4):619-633.
4. CattaneoM (2011) The platelet P2Y receptor for adenosine diphosphate: Congenital and drug-induced defects. Blood 117(7):2102-2112.
5. Vane JR (1994) The Croonian Lecture, 1993. The endothelium: Maestro of the blood circulation. Philos Trans R Soc Lond B Biol Sci 343(1304):225-246.
6. Freedman JE, et al. (1999) Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res 84(12):1416-1421.
7. Radomski MW, Palmer RM, Moncada S (1990) An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87(13): 5193-5197.
8. Cattaneo M, Lecchi A (2007) Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 5(3):577-582.
9. Iyú D, et al. (2011) P2Y and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets 22(7):504-515.
10. Murata T, et al. (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388(6643):678-682.
11. Ozüyaman B, et al. (2005) Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation. Thromb Haemost 93(6):1161-1167.
12. Antl M, et al. (2007) IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood 109(2):552-559.
13. Dangel O, et al. (2010) Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition. J Thromb Haemost 8(6):1343-1352.
14. Schinner E, Salb K, Schlossmann J (2011) Signaling via IRAG is essential for NO/cGMPdependent inhibition of platelet activation. Platelets 22(3):217-227.
15. Moore C, Tymvios C, Emerson M (2010) Functional regulation of vascular and platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase. Thromb Haemost 104(2):342-349.
16. Broeders MA, Tangelder GJ, Slaaf DW, Reneman RS, Egbrink MG (2001) Endogenous nitric oxide and prostaglandins synergistically counteract thromboembolism in arterioles but not in venules. Arterioscler Thromb Vasc Biol 21(1):163-169.
17. Broeders MA, Tangelder GJ, Slaaf DW, Reneman RS, oude Egbrink MG (1998) Endogenous nitric oxide protects against thromboembolism in venules but not in arterioles. Arterioscler Thromb Vasc Biol 18(1):139-145.
18. Radomski MW, Palmer RM, Moncada S (1987) The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol 92(3):639-646.
19. Vilahur G, Pena E, Padró T, Badimon L (2007) Protein disulphide isomerase-mediated LA419-NO release provides additional antithrombotic effects to the blockade of the ADP receptor. Thromb Haemost 97(4):650-657.
20. Vilahur G, Segalés E, Salas E, Badimon L (2004) Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow-and lesiondependent thrombosis in the porcine ex vivo model. Circulation 110(12):1686-1693.
21. Tallarida RJ (2006) An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319(1):1-7.
22. Fälker K, Lange D, Presek P (2004) ADP secretion and subsequent P2Y12 receptor signalling play a crucial role in thrombin-induced ERK2 activation in human platelets. Thromb Haemost 92(1):114-123.
23. Maurice DH, Haslam RJ (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37(5):671-681.
24. Dickinson NT, Jang EK, Haslam RJ (1997) Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: Effects on platelet aggregation. Biochem J 323(Pt 2):371-377.
25. Butt E, et al. (1994) cAMP-and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 269(20):14509-14517.
26. Hidaka H, Asano T (1976) Human blood platelet 3?: 5?-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase. Biochim Biophys Acta 429(2):485-497.
27. Burkhardt M, et al. (2000) KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells. J Biol Chem 275(43): 33536-33541.
28. Taylor MS, et al. (2004) Inhibition of cGMP-dependent protein kinase by the cellpermeable peptide DT-2 reveals a novel mechanism of vasoregulation. Mol Pharmacol 65(5):1111-1119.
29. Danielewski O, Schultess J, Smolenski A (2005) The NO/cGMP pathway inhibits Rap activation in human platelets via cGMP-dependent protein kinase I. Thromb Haemost 93(2):319-325.
30. Aszódi A, et al. (1999) The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP-and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 18(1):37-48.
31. Kim S, et al. (2002) Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 99(10):3629-3636.
32. Chan MV, Armstrong PC, Papalia F, Kirkby NS, Warner TD (2011) Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing. Platelets 22(7):485-494.